RG 7212

Drug Profile

RG 7212

Alternative Names: Anti-TWEAK MAb - Roche; Anti-TWEAK monoclonal antibody - Roche; RG-7212; RO-5458640

Latest Information Update: 03 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action TNFSF12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 30 Jan 2014 Discontinued - Phase-I for Solid tumours in Canada, Denmark and the Netherlands (IV)
  • 01 Mar 2013 Roche completes a phase I multiple-ascending dose trial in Solid tumours (late stage disease) in Canada, Denmark and the Netherlands (NCT01383733)
  • 01 Jul 2011 Phase-I clinical trials in Solid tumours in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top